Adam M Leventhal1,2, Hongying Dai3. 1. Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. 2. Department of Psychology, University of Southern California, Los Angeles, CA, USA. 3. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
Abstract
BACKGROUND: Evidence of US adult flavored e-cigarette use prevalence stratified by age, smoking status, and purpose for vaping (ie, quitting smoking, to use when or where smoking is not allowed) can inform policies that reduce the tobacco-related cancer burden. METHODS: Current flavored e-cigarette use (use 1 or more nontobacco flavors) prevalence estimates were compared across subpopulation groups using 2-sided statistical significance tests in the July 2018 Current Population Survey Tobacco Use Supplement, a nationally representative cross-sectional adult survey (n = 46 759). RESULTS: Current flavored e-cigarette use was reported by 1.6% (95% confidence interval [CI] = 1.47% to 1.69%) of all respondents. Among current vapers, the percentage of those who used flavored e-cigarettes was higher for adults aged 18-24 years (89.6%), 25-34 years (86.7%), and 35-44 years (76.0%) than for adults aged 45 years and older (60.4%, Ps < .001); was higher in never smokers (89.8%) than current (72.9%), long-term former (73.9%), and recent former (80.4%) smokers (Ps ≤ .009); was higher in smokers who reportedly did (78.9%) vs did not (71.1%) use e-cigarettes to vape where or when smoking is not allowed (P = .005); and did not differ between smokers who reportedly did (75.0%) vs did not (73.9%) vape to quit smoking (P = .71). Individuals who vaped to quit smoking and currently used flavored e-cigarettes constituted 0.9% (95% CI = 0.82% to 0.99%) of all adults (weighted N = 2 251 000, 95% CI = 2 046 000 to 2 476 000) and 57.2% of current flavored e-cigarette users. CONCLUSIONS: Flavored e-cigarette use prevalence was low among US adults overall but common for current vapers. Flavored e-cigarette use was disproportionately prevalent among never smokers and other subpopulations that might experience harm from vaping.
BACKGROUND: Evidence of US adult flavored e-cigarette use prevalence stratified by age, smoking status, and purpose for vaping (ie, quitting smoking, to use when or where smoking is not allowed) can inform policies that reduce the tobacco-related cancer burden. METHODS: Current flavored e-cigarette use (use 1 or more nontobacco flavors) prevalence estimates were compared across subpopulation groups using 2-sided statistical significance tests in the July 2018 Current Population Survey Tobacco Use Supplement, a nationally representative cross-sectional adult survey (n = 46 759). RESULTS: Current flavored e-cigarette use was reported by 1.6% (95% confidence interval [CI] = 1.47% to 1.69%) of all respondents. Among current vapers, the percentage of those who used flavored e-cigarettes was higher for adults aged 18-24 years (89.6%), 25-34 years (86.7%), and 35-44 years (76.0%) than for adults aged 45 years and older (60.4%, Ps < .001); was higher in never smokers (89.8%) than current (72.9%), long-term former (73.9%), and recent former (80.4%) smokers (Ps ≤ .009); was higher in smokers who reportedly did (78.9%) vs did not (71.1%) use e-cigarettes to vape where or when smoking is not allowed (P = .005); and did not differ between smokers who reportedly did (75.0%) vs did not (73.9%) vape to quit smoking (P = .71). Individuals who vaped to quit smoking and currently used flavored e-cigarettes constituted 0.9% (95% CI = 0.82% to 0.99%) of all adults (weighted N = 2 251 000, 95% CI = 2 046 000 to 2 476 000) and 57.2% of current flavored e-cigarette users. CONCLUSIONS: Flavored e-cigarette use prevalence was low among US adults overall but common for current vapers. Flavored e-cigarette use was disproportionately prevalent among never smokers and other subpopulations that might experience harm from vaping.
Authors: Michèle G Bonhomme; Enver Holder-Hayes; Bridget K Ambrose; Cindy Tworek; Shari P Feirman; Brian A King; Benjamin J Apelberg Journal: Tob Control Date: 2016-10-28 Impact factor: 7.552
Authors: Adam M Leventhal; Richard Miech; Jessica Barrington-Trimis; Lloyd D Johnston; Patrick M O'Malley; Megan E Patrick Journal: JAMA Date: 2019-12-03 Impact factor: 56.272
Authors: Liane M Schneller; Maansi Bansal-Travers; Maciej L Goniewicz; Scott McIntosh; Deborah Ossip; Richard J O'Connor Journal: PLoS One Date: 2018-08-23 Impact factor: 3.240
Authors: Teresa W Wang; Andrea S Gentzke; MeLisa R Creamer; Karen A Cullen; Enver Holder-Hayes; Michael D Sawdey; Gabriella M Anic; David B Portnoy; Sean Hu; David M Homa; Ahmed Jamal; Linda J Neff Journal: MMWR Surveill Summ Date: 2019-11-06
Authors: Ahmed Jamal; Elyse Phillips; Andrea S Gentzke; David M Homa; Stephen D Babb; Brian A King; Linda J Neff Journal: MMWR Morb Mortal Wkly Rep Date: 2018-01-19 Impact factor: 17.586
Authors: Julie B Wang; Jeffrey E Olgin; Gregory Nah; Eric Vittinghoff; Janine K Cataldo; Mark J Pletcher; Gregory M Marcus Journal: PLoS One Date: 2018-07-25 Impact factor: 3.240
Authors: Maciej L Goniewicz; Danielle M Smith; Kathryn C Edwards; Benjamin C Blount; Kathleen L Caldwell; Jun Feng; Lanqing Wang; Carol Christensen; Bridget Ambrose; Nicolette Borek; Dana van Bemmel; Karen Konkel; Gladys Erives; Cassandra A Stanton; Elizabeth Lambert; Heather L Kimmel; Dorothy Hatsukami; Stephen S Hecht; Raymond S Niaura; Mark Travers; Charles Lawrence; Andrew J Hyland Journal: JAMA Netw Open Date: 2018-12-07
Authors: Nathan Silver; Padmini Kucherlapaty; Ganna Kostygina; Hy Tran; Miao Feng; Sherry Emery; Barbara Schillo Journal: Int J Environ Res Public Health Date: 2022-06-23 Impact factor: 4.614
Authors: Elise M Stevens; Brittney Keller-Hamilton; Darren Mays; Jennifer B Unger; Olivia A Wackowski; Julia C West; Andrea C Villanti Journal: Int J Environ Res Public Health Date: 2021-12-09 Impact factor: 4.614